GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1514
- Registration Number
- NCT05633654
- Locations
- 🇺🇸
Hunterdon Medical Center, Flemington, New Jersey, United States
🇺🇸Franciscan Health Munster, Munster, Indiana, United States
🇺🇸Sacred Heart Medical Oncology Group, Pensacola, Florida, United States
Study of Novel Treatment Combinations in Patients With Lung Cancer
- Conditions
- Lung CancerResectable Non-Small-Cell Lung CancerAdvanced or Metastatic Non-Small-Cell Lung Cancer
- Interventions
- Drug: Domvanalimab (DOM)Drug: Sacituzumab govitecan-hziy (SG)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 593
- Registration Number
- NCT05633667
- Locations
- 🇬🇧
St. Bartholomew's Hospital,Substudy-01, London, United Kingdom
🇬🇧St. Bartholomew's Hospital,Substudy-02, London, United Kingdom
🇬🇧St. Bartholomew's Hospital,Substudy-03, London, United Kingdom
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
- Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Drug: Edecesertib Placebo
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT05629208
- Locations
- 🇺🇸
ARENSIA Exploratory Medicine, LLC, Phoenix, Arizona, United States
🇺🇸Center for Dermatology Clinical Research Inc., Fremont, California, United States
🇺🇸UCSD Perlman Medical Offices, La Jolla, California, United States
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT05627466
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 468
- Registration Number
- NCT05603143
- Locations
- 🇵🇹
Hospital CUF Descobertas, Lisboa, Portugal
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇧🇬Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia, Bulgaria
Study of Novel Antiretrovirals in Participants With HIV-1
- Conditions
- HIV-1-infection
- Interventions
- Drug: B/F/TAFDrug: Standard of Care (Substudy 01)Drug: Standard of Care (Substudy 02)Drug: Standard of Care (Substudy 03)
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 49
- Registration Number
- NCT05585307
- Locations
- 🇺🇸
Washington Health Institute,Substudy-02, Washington, District of Columbia, United States
🇺🇸Washington Health Institute,Substudy-01, Washington, District of Columbia, United States
🇺🇸Washington Health Institute,Substudy-03, Washington, District of Columbia, United States
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 689
- Registration Number
- NCT05502341
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1069
- Registration Number
- NCT05502237
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, China
🇨🇳Deyang People's Hospital, Deyang, China
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT05458102
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸Collaborative Neuroscience Research, LLC., Long Beach, California, United States
🇺🇸Triple O Research Institute, P.A., West Palm Beach, Florida, United States
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast CancerPD-L1 Positive
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 440
- Registration Number
- NCT05382286
- Locations
- 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Magee-Womens Hospital of UPMC,5115 Centre Avenue, Pittsburgh, Pennsylvania, United States